Navigation Links
Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
Date:1/5/2012

RICHMOND, Calif., Jan. 5, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 7:30 am PT (10:30 am ET) on Thursday, January 12, 2012, at the 30th Annual J.P. Morgan Healthcare Conference which will be held in San Francisco.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. Sangamo has ongoing clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS.  Other therapeutic programs are focused on monogenic diseases, including hemophilia and hemoglobinopathies.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function.  Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification.  Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
2. Sangamo BioSciences Announces Presentation at the Lazard Capital Markets 8th Annual Healthcare Conference
3. Sangamo BioSciences Reports Third Quarter 2011 Financial Results
4. Sangamo BioSciences Announces Third Quarter 2011 Conference Call and Webcast
5. Sangamo BioSciences Announces Presentation at the 18th Annual Newsmakers in the Biotech Industry Conference
6. Sangamo BioSciences Announces Presentation at the 2011 UBS Global Life Sciences Conference
7. Sangamo BioSciences Reports Second Quarter 2011 Financial Results
8. Sangamo BioSciences Announces Efficient Generation of Transgenic Pigs Using Zinc Finger Nuclease (ZFN) Technology
9. Sangamo BioSciences Announces Second Quarter 2011 Conference Call and Webcast
10. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
11. Sangamo Announces Pricing of Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Dallas, Texas (PRWEB) August 21, 2014 ... Global Seaweed Fertilizer Industry” is a professional ... Fertilizer market. The report provides basic Seaweed ... application, and industry chain structure as well ... international market analysis, including domestic market as ...
(Date:8/21/2014)... August 21, 2014 The College of ... private college in the Mid-Hudson Region to be designated ... begin accepting applications from qualified “high-technology” businesses that align ... very pleased to have been selected for the START-UP ... transformative initiative to stimulate economic development in New York ...
(Date:8/21/2014)... HONG KONG , Aug. 21, 2014  China Cord ... today announced its plan to release financial results for ... August 28, 2014, after market close in the US.  ... call at 8:00 a.m. ET on Friday, August 29, ... brief overview of the Company,s recent developments, followed by ...
(Date:8/21/2014)... August 21, 2014 Gallus ... contract development and manufacturing organization (CMO) announced today ... Inc., an oncology company focused on the development ... to manufacture the anti-prostate specific membrane antigen (PSMA) ... candidate. Under the agreement the antibody will ...
Breaking Biology Technology:Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 3The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3
... HAIFA, Israel, April 14 ES Vascular Ltd. ... approval for its Open Aortic Stapler,(OAS) system for ... repair of AAA and other aortic reconstructions, enabling,commercialization ... on its,proprietary stapling technology, the OAS stapler is ...
... France, April 14 /PRNewswire-FirstCall/,-- Cephalon, Inc. (Nasdaq: ... granted marketing authorization for EFFENTORA(TM), a buccal,tablet formulation ... of,breakthrough cancer pain (BTCP) in adult patients who ... The approval allows Cephalon,to market EFFENTORA in the ...
... HAYWARD, Calif., April 14 Metabolex, Inc., ... development of,proprietary new medicines for the treatment ... Hill has joined the company as chief,financial ... strategic,planning experience to Metabolex, including expertise in ...
Cached Biology Technology:ES Vascular Receives CE Mark for its First Aortic Stapler for End-to-End Anastomosis Between Synthetic Grafts and Aorta During Open Repair of Aortic Aneurysmal and Occlusive Disease 2Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain 2Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain 3Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain 4Metabolex Appoints Donald Hill as Chief Financial Officer 2
(Date:8/21/2014)... aimed at improving the food intake, health and quality ... is among three projects at the University of Waterloo ... Canadian Institutes of Health Research (CIHR). , Professor ... at Waterloo, and a Schlegel research chair in nutrition ... investigate why many Canadians living in long-term care homes ...
(Date:8/21/2014)... that has implications for life in other extreme environments, ... system, LSU Associate Professor of Biological Sciences Brent Christner ... or NSF, this week published a paper confirming that ... 800 meters (2600 feet) beneath the surface of the ... that more than 400 subglacial lakes and numerous rivers ...
(Date:8/21/2014)... heard of the water window? It consists of radiations ... not absorbed by the water in biological tissues. New ... coherent radiations within the water window. These could be ... high-contrast image of the biological samples or to be ... identifies the physical mechanism needed to efficiently generate the ...
Breaking Biology News(10 mins):Grants will fund landmark aging research at Waterloo 2800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 2800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 3800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 4Water window imaging opportunity 2
... forms that have been around since the dinosaurs, could ... because they can simultaneously produce other valuable products such ... Engineers at Oregon State University concede that such technology ... science fiction many of the needed advances have ...
...  MedNet Solutions, a global life sciences technology company specializing ... that the latest version of iMedNet ™ ... EDC is a ground-breaking eClinical solution that makes ... type of research initiative...even very small studies of short ...
... press release is available in German . ... Department of Limnology of the University of Vienna unravels the ... the unexpected biogeochemical complexity of dissolved organic matter locked in ... streams. Their paper, now published in Nature Geoscience , ...
Cached Biology News:Ancient diatoms could make biofuels, electronics and health food -- at the same time 2MedNet Solutions Announces Latest Enhancements To Its iMedNet EDC eClinical Solution 2Alpine glaciers contribute to carbon cycling 2
EDG-1CT (endothelial cell differentiation gene-1, C terminal)...
Mouse Anti-human CD11b/Mac-1alpha, clone LM2/1, Monoclonal Antibody...
Mouse monoclonal [1-N-14] to Adenovirus Type 7 hexon C11 Immunogen: Purified Adenovirus type 7 Specificity: This antibody is specific for Adenovirus type 7 hexon C11....
... Kir2.1 protein. The epitope is specific ... in any other known protein.,SPECIES REACTIVITIES: ... in rabbit, bovine, porcine and guinea ... rat and mouse (17/19 residues) and ...
Biology Products: